Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2947088 | 0.94 | IDO1 (0.39) | IDO1NPSR1MAPTMEN1KMT2A | |
| SCHEMBL2959756 | 0.91 | IDO1 (0.37) | IDO1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL2959762 | 0.89 | CDK4 (0.38) | IDO1NPSR1MAPTSMN1; SMN2POLB | |
| SCHEMBL2958483 | 0.88 | CYP3A4 (0.39) | MAPTMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL2952051 | 0.88 | IDO1 (0.38) | IDO1NPSR1MAPTMEN1KMT2A | |
| SCHEMBL2954060 | 0.88 | NPC1 (0.37) | IDO1NPSR1MAPTMEN1KMT2A | |
| SCHEMBL2958074 | 0.88 | MAP2K1 (0.39) | MAPTSMN1; SMN2POLB | |
| SCHEMBL2952663 | 0.87 | EGFR (0.38) | MAPTMEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL2960654 | 0.87 | RAPGEF4 (0.38) | IDO1NPSR1MAPTSMN1; SMN2RAB9A | |
| SCHEMBL2961083 | 0.86 | MAPT (0.39) | IDO1NPSR1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | claimed |
| US-20080207907-A1 | Reacting an aryl halide and amine; using palladium catalyst system with solvent mixture | UCB PHARMA, S.A. (BE) | 2008-08-28 | — | — | US | claimed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | claimed |
| US-7763729-B2 | Bicyclic heteroaromatic derivatives | UCB PHARMA S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | CELLTECH R&D LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7482452-B2 | Process for preparing 3-aminothienopyridone derivatives | CELLTECH R&D LIMITED (GB) | 2009-01-27 | — | — | US | disclosed |
| EP-1638980-B1 | PROCESS FOR PREPARING 3-AMINOTHIENOPYRIDONE DERIVATIVES | UCB PHARMA SA (BE) | 2008-11-05 | — | — | EP | disclosed |
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20080207907-A1 | Reacting an aryl halide and amine; using palladium catalyst system with solvent mixture | UCB PHARMA, S.A. (BE) | 2008-08-28 | — | — | US | disclosed |
| US-20070191608-A1 | Process for preparing 3-aminothienopyridone derivatives | CELLTECH R&D LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| EP-1817313-A1 | PROCESS FOR PD-CATALYSED C-N COUPLING IN SPECIFIC SOLVENT SYSTEMS | UCB Pharma, S.A. (BE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056412-A1 | PROCESS FOR PD-CATALYSED C-N COUPLING IN SPECIFIC SOLVENT SYSTEMS | UCB PHARMA, S.A. (BE) | 2006-06-01 | — | — | WO | disclosed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191608-A1 | Process for preparing 3-aminothienopyridone derivatives | MAPK3, MAP3K6, MAP4K1 | IDO1 1258/4885NPSR1 2977/4885MAPT 712/4885 |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | MAPK1, CNKSR1, ALK | IDO1 100/4885NPSR1 916/4885MAPT 4305/4885 |
| US-20080207907-A1 | Reacting an aryl halide and amine; using palladium catalyst system with solvent mixture | AHR, PDCD1LG2, DDT | IDO1 29/4885NPSR1 650/4885MAPT 1216/4885 |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | MAPK1, CNKSR1, CBR1 | IDO1 215/4885NPSR1 844/4885MAPT 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.